About Merus NV

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

At the moment the company generates 30M USD in revenues.

On its last earning announcement, the company reported a loss of -1.14$ per share.

The book value per share is 2.71$

Merus NV website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
30M - -41M -135.80% -27M -1.14 - - 23M 2.71 -50M -4M -54M